Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

56
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
56
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

494
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
494
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

577
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
577
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MulAFNet: Integrating Multiple Molecular Representations for Enhanced Property Prediction.

ACS omega·2025
Same author

Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.

Cancer communications (London, England)·2018
Same author

[Expression of Nerve Growth Factor and Type 3 of Acid Sensitive Ion Channels in Rat Model of Type â…¢ Prostatitis].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2018
Same author

[Expression of AXIN and MACC1 in Gastric Carcinoma and Its Clinical Significance].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2018
Same author

Coexistence of NDM-1-producing Escherichia coli and Citrobacter freundii in the same patient.

Journal of global antimicrobial resistance·2018
Same author

Broadband microwave absorption utilizing water-based metamaterial structures.

Optics express·2018

Related Experiment Video

Updated: Jun 3, 2025

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

1.7K

MMSG-DTA: A Multimodal, Multiscale Model Based on Sequence and Graph Modalities for Drug-Target Affinity Prediction.

Jiahao Xu1,2, Lei Ci1, Bo Zhu1

  • 1School of Information Engineering, Huzhou University, Huzhou 313000, China.

Journal of Chemical Information and Modeling
|January 8, 2025
PubMed
Summary

This study introduces MMSG-DTA, a novel model for drug-target affinity (DTA) prediction. It enhances accuracy by integrating molecular graph and protein sequence data for better drug discovery insights.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Related Experiment Videos

Last Updated: Jun 3, 2025

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

1.7K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Area of Science:

  • Computational chemistry
  • Bioinformatics
  • Drug discovery

Background:

  • Drug-Target Affinity (DTA) prediction is crucial for drug discovery but current methods struggle with molecular graph and protein feature extraction.
  • Existing models often fail to capture global molecular graph features and rely on limited 1D protein sequences, hindering accurate interaction modeling.

Purpose of the Study:

  • To develop an advanced model, MMSG-DTA, for improved Drug-Target Affinity prediction.
  • To address limitations in capturing global molecular graph features and enhance protein representation for better drug-target interaction analysis.

Main Methods:

  • Proposed a multimodal, multiscale model (MMSG-DTA) combining graph neural networks and Transformers for molecular graph feature extraction.
  • Utilized a graph-based modality for improved protein feature extraction from amino acid sequences.
  • Incorporated an attention-based feature fusion module to integrate diverse feature types for enhanced representation capacity.

Main Results:

  • MMSG-DTA demonstrated superior performance in DTA prediction across three benchmark datasets (Davis, KIBA, Metz).
  • The model effectively captured both local and global features from molecular graphs and improved protein representation.
  • Experimental results showed MMSG-DTA outperformed several state-of-the-art DTA prediction methods.

Conclusions:

  • The proposed MMSG-DTA model significantly advances the accuracy and robustness of drug-target interaction prediction.
  • The multimodal and multiscale approach effectively integrates diverse data modalities for comprehensive feature learning.
  • This work provides a powerful tool for accelerating drug discovery and development through enhanced DTA prediction.